Deciphera Pharmaceuticals Inc是一家专注于发现、开发和提供药物治疗癌症患者的生物制药公司。该公司开发了激酶生物学的开关控制激酶抑制剂平台,以执行其战略,开发广泛的药物组合。该公司已经批准了一种药物,QINLOCK,这是一种开关控制激酶抑制剂,用于治疗第四线胃肠道间质瘤(GIST)。此外,该公司正在开发三种临床阶段候选药物,其中包括Vimseltinib(DCC-3014)-集落刺激因子1受体(CSF1R)激酶抑制腱鞘巨细胞瘤(TGCT),Rebastinib-TEK酪氨酸激酶(TIE2)激酶抑制晚期或转移性实体瘤,和DCC-3116-ULK激酶抑制突变RAS/RAF癌。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Filip Janku | Member of Scientific Advisory Board | 2015 | 52 |
| F. Stephen Hodi | Member of Scientific Advisory Board | 2015 | - |
| Jean-Yves Blay | Member of Scientific Advisory Board | 2015 | 64 |
| John S. Condeelis | Member of Scientific Advisory Board | - | - |
| John de Groot | Member of Scientific Advisory Board | - | - |
| Michele De Palma | Member of Scientific Advisory Board | - | - |
| Toichi Takino | Director | 2024 | 58 |
| Masayuki Tanigawa | Director | 2024 | - |